{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:06:19Z","timestamp":1794607579941,"version":"4.9.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2014.10.004","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T14:37:06Z","timestamp":1414420626000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk\/benefit assessment"],"prefix":"10.1016","volume":"33","author":[{"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Seligman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Condit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Marie","family":"Mac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baevin","family":"Carbery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14760584.6.2.255","article-title":"Use of viral vectors for the development of vaccines","volume":"6","author":"Liniger","year":"2007","journal-title":"Expert Rev Vaccines."},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biologicals.2010.03.005","article-title":"Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference","volume":"38","author":"Excler","year":"2010","journal-title":"Biologicals."},{"issue":"9","key":"10.1016\/j.vaccine.2014.10.004_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-3024.2009.01141.x","article-title":"Viral vectors in malaria vaccine development","volume":"31","author":"Limbach","year":"2009","journal-title":"Parasite Immunol."},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2014.10.004_bib0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tube.2006.01.017","article-title":"Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization","volume":"86","author":"Xing","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"issue":"3","key":"10.1016\/j.vaccine.2014.10.004_bib0025","doi-asserted-by":"crossref","DOI":"10.4161\/hv.23220","article-title":"Applications and challenges of multivalent recombinant vaccines","volume":"9","author":"Naim","year":"2012","journal-title":"Hum Vaccin Immunother."},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/COH.0b013e328363d3b7","article-title":"Nonreplicating vectors in HIV vaccines","volume":"8","author":"Johnson","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/COH.0b013e328363d389","article-title":"Development of replication-competent viral vectors for HIV vaccine delivery","volume":"8","author":"Parks","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"43","key":"10.1016\/j.vaccine.2014.10.004_bib0040","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine."},{"issue":"9944","key":"10.1016\/j.vaccine.2014.10.004_bib0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(14)61371-4","article-title":"Experimental Ebola drugs enter the limelight","volume":"384","author":"Mullard","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0050","unstructured":"WHO Initiative for Vaccine Research. WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors December 2003. Accessed from: http:\/\/www.who.int\/vaccine_research\/documents\/vvreport\/en\/index1.html on 30 October 2014."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2014.10.004_bib0055","doi-asserted-by":"crossref","first-page":"B108","DOI":"10.1016\/j.vaccine.2012.10.119","article-title":"Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization","volume":"31","author":"Amarasinghe","year":"2013","journal-title":"Vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.biologicals.2011.08.001","article-title":"Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system?","volume":"40","author":"MacDonald","year":"2012","journal-title":"Biologicals."},{"issue":"7","key":"10.1016\/j.vaccine.2014.10.004_bib0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3928\/0090-4481-19980701-11","article-title":"Vaccine safety: current and future challenges","volume":"27","author":"Chen","year":"1998","journal-title":"Pediatr Ann."},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.851","article-title":"The Brighton Collaboration: enhancing comparability of vaccine safety data","volume":"12","author":"Kohl","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0075","series-title":"Vaccines","first-page":"870","article-title":"Yellow fever vaccine","author":"Monath","year":"2012"},{"issue":"20","key":"10.1016\/j.vaccine.2014.10.004_bib0080","first-page":"201","volume":"88","year":"2013","journal-title":"Rec."},{"issue":"9276","key":"10.1016\/j.vaccine.2014.10.004_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet."},{"issue":"9276","key":"10.1016\/j.vaccine.2014.10.004_bib0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet."},{"issue":"9276","key":"10.1016\/j.vaccine.2014.10.004_bib0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine","volume":"358","author":"Chan","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0100","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine."},{"issue":"10","key":"10.1016\/j.vaccine.2014.10.004_bib0105","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3201\/eid1710.101789","article-title":"Yellow fever virus vaccine-associated deaths in young women","volume":"17","author":"Seligman","year":"2011","journal-title":"Emerg Infect Dis."},{"issue":"9438","key":"10.1016\/j.vaccine.2014.10.004_bib0110","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(04)17017-7","article-title":"History of thymoma and yellow fever vaccination","volume":"364","author":"Barwick Eidex","year":"2004","journal-title":"Lancet."},{"issue":"33","key":"10.1016\/j.vaccine.2014.10.004_bib0115","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine."},{"issue":"4715","key":"10.1016\/j.vaccine.2014.10.004_bib0120","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.4023707","article-title":"Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution","volume":"229","author":"Rice","year":"1985","journal-title":"Science."},{"issue":"6","key":"10.1016\/j.vaccine.2014.10.004_bib0125","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0130","doi-asserted-by":"crossref","unstructured":"Chen RT, Carbery B, Mac L, Berns KI, Chapman L, Condit RC, et al. The Brighton Collaboration Viral Vector Vaccine Safety Working Group (V3SWG). Vaccine. 2014 In press, Doi: 10.1016\/j.vaccine.2014.09.035.","DOI":"10.1016\/j.vaccine.2014.09.035"},{"issue":"48","key":"10.1016\/j.vaccine.2014.10.004_bib0135","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine."},{"issue":"11","key":"10.1016\/j.vaccine.2014.10.004_bib0140","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"43","key":"10.1016\/j.vaccine.2014.10.004_bib0145","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine."},{"issue":"14","key":"10.1016\/j.vaccine.2014.10.004_bib0150","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0155","first-page":"131","article-title":"Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection","volume":"85","author":"Kengsakul","year":"2002","journal-title":"J Med Assoc Thai."},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0160","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.provac.2010.07.012","article-title":"Yellow fever vaccine post-marketing surveillance in Brazil","author":"Martins","year":"2010","journal-title":"Procedia Vaccinol."},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0165","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients","volume":"48","author":"Veit","year":"2009","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0170","series-title":"Summary information on referral opinion pursuant to article 30 of council directive 2001\/83\/EC for stamaril and associated names","first-page":"1","year":"2006"},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0175","first-page":"130","article-title":"Transmission of yellow fever vaccine virus through breast-feeding\u2014Brazil, 2009","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"10.1016\/j.vaccine.2014.10.004_bib0180","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.10.004_bib0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-3527(03)60009-6","article-title":"Pathogenesis and pathophysiology of yellow fever","volume":"60","author":"Monath","year":"2003","journal-title":"Adv Virus Res."},{"issue":"17","key":"10.1016\/j.vaccine.2014.10.004_bib0190","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"10.1016\/j.vaccine.2014.10.004_bib0195","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue: West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/oxfordjournals.aje.a121232","article-title":"Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans","volume":"93","author":"Monath","year":"1971","journal-title":"Am J Epidemiol."},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/648731","article-title":"Persistent infection with West Nile virus years after initial infection","volume":"201","author":"Murray","year":"2010","journal-title":"J Infect Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/JVI.77.1.25-36.2003","article-title":"Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis","volume":"77","author":"Gritsun","year":"2003","journal-title":"J Virol."},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.01775-10","article-title":"Detection of yellow fever 17D genome in urine","volume":"49","author":"Domingo","year":"2011","journal-title":"J Clin Microbiol."},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0220","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/527328","article-title":"Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes","volume":"197","author":"McGee","year":"2008","journal-title":"J Infect Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0225","first-page":"659","article-title":"Experimental infection of Culex annulirostris","volume":"75","author":"Reid","year":"2006","journal-title":"Culex gelidus, and Aedes vigilax with a yellow fever\/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg."},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0230","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.2000.62.480","article-title":"Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF\/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes","volume":"62","author":"Bhatt","year":"2000","journal-title":"Am J Trop Med Hyg."},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0235","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2004.70.89","article-title":"Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction","volume":"70","author":"Johnson","year":"2004","journal-title":"Am J Trop Med Hyg."},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0240","doi-asserted-by":"crossref","first-page":"986","DOI":"10.4269\/ajtmh.2006.75.986","article-title":"Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand","volume":"75","author":"Higgs","year":"2006","journal-title":"Am J Trop Med Hyg."},{"issue":"11","key":"10.1016\/j.vaccine.2014.10.004_bib0245","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/vbz.2011.0947","article-title":"Evaluation of chimeric yellow fever 17D\/dengue viral replication in ticks","volume":"12","author":"Kazimirova","year":"2012","journal-title":"Vector Borne Zoonotic Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0250","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol."},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/590187","article-title":"Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes","volume":"198","author":"Pulendran","year":"2008","journal-title":"J Infect Dis."},{"issue":"10","key":"10.1016\/j.vaccine.2014.10.004_bib0260","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat Rev Immunol."},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","article-title":"Treatment of yellow fever","volume":"78","author":"Monath","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0270","series-title":"Replicating vaccines: a new generation","first-page":"349","article-title":"Recombinant, chimeric, live, attenuated vaccines against Flaviviruses and Alphaviruses","author":"Monath","year":"2010"},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0275","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1128\/JVI.75.2.934-942.2001","article-title":"Molecular basis for attenuation of neurovirulence of a yellow fever Virus\/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)","volume":"75","author":"Arroyo","year":"2001","journal-title":"J Virol."},{"issue":"5","key":"10.1016\/j.vaccine.2014.10.004_bib0280","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/527329","article-title":"Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates","volume":"197","author":"McGee","year":"2008","journal-title":"J Infect Dis."},{"issue":"12","key":"10.1016\/j.vaccine.2014.10.004_bib0285","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/v5123048","article-title":"Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus","volume":"5","author":"Dayan","year":"2013","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-1702(98)00036-7","article-title":"Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations","volume":"55","author":"Xie","year":"1998","journal-title":"Virus Res."},{"issue":"9426","key":"10.1016\/j.vaccine.2014.10.004_bib0295","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(04)16459-3","article-title":"Live flavivirus vaccines: reasons for caution","volume":"363","author":"Seligman","year":"2004","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.vaccine.2014.10.004_bib0300","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1016\/j.vaccine.2004.11.069","article-title":"Recombination and flavivirus vaccines: a commentary","volume":"23","author":"Monath","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2014.10.004_bib0305","doi-asserted-by":"crossref","first-page":"e23247","DOI":"10.1371\/journal.pone.0023247","article-title":"Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus","volume":"6","author":"McGee","year":"2011","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0310","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/JVI.01063-09","article-title":"A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination","volume":"84","author":"Taucher","year":"2010","journal-title":"J Virol."},{"issue":"37\u201338","key":"10.1016\/j.vaccine.2014.10.004_bib0315","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1016\/j.vaccine.2007.07.016","article-title":"Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE)","volume":"25","author":"Pugachev","year":"2007","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2014.10.004_bib0320","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0264-410X(01)00439-X","article-title":"Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing","volume":"20","author":"Pugachev","year":"2002","journal-title":"Vaccine."},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2014.10.004_bib0325","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1099\/0022-1317-56-2-363","article-title":"Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus","volume":"56","author":"Liprandi","year":"1981","journal-title":"J Gen Virol."},{"issue":"3","key":"10.1016\/j.vaccine.2014.10.004_bib0330","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/infdis\/169.3.512","article-title":"Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis","volume":"169","author":"Jennings","year":"1994","journal-title":"J Infect Dis."},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0335","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/viro.2001.1168","article-title":"Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil","volume":"290","author":"Galler","year":"2001","journal-title":"Virology."},{"issue":"38","key":"10.1016\/j.vaccine.2014.10.004_bib0340","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1016\/j.vaccine.2011.06.101","article-title":"Genetic stability of a dengue vaccine based on chimeric yellow fever\/dengue viruses","volume":"29","author":"Mantel","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0345","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","article-title":"Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis","volume":"257","author":"Guirakhoo","year":"1999","journal-title":"Virology."},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0350","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/JVI.78.2.1032-1038.2004","article-title":"High fidelity of yellow fever virus RNA polymerase","volume":"78","author":"Pugachev","year":"2004","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2014.10.004_bib0355","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.vaccine.2006.06.082","article-title":"High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production","volume":"25","author":"Barban","year":"2007","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2014.10.004_bib0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1743-422X-5-27","article-title":"Constancy and diversity in the flavivirus fusion peptide","volume":"5","author":"Seligman","year":"2008","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.vaccine.2014.10.004_bib0365","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2746\/042516407X214473","article-title":"Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses","volume":"39","author":"Long","year":"2007","journal-title":"Equine Vet J."},{"issue":"2","key":"10.1016\/j.vaccine.2014.10.004_bib0370","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","article-title":"Yellow fever vaccine-associated viscerotropic disease and death in Spain","volume":"36","author":"Doblas","year":"2006","journal-title":"J Clin Virol."},{"issue":"3","key":"10.1016\/j.vaccine.2014.10.004_bib0375","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biologicals.2005.03.009","article-title":"Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys","volume":"33","author":"Monath","year":"2005","journal-title":"Biologicals."},{"issue":"22","key":"10.1016\/j.vaccine.2014.10.004_bib0380","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0385","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/JVI.74.4.1742-1751.2000","article-title":"Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys","volume":"74","author":"Monath","year":"2000","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2014.10.004_bib0390","doi-asserted-by":"crossref","first-page":"13797","DOI":"10.1128\/JVI.79.21.13797-13799.2005","article-title":"Dengue fever in humanized NOD\/SCID mice","volume":"79","author":"Bente","year":"2005","journal-title":"J Virol."},{"issue":"6","key":"10.1016\/j.vaccine.2014.10.004_bib0395","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1128\/JVI.02273-08","article-title":"Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus","volume":"83","author":"Lobigs","year":"2009","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2014.10.004_bib0400","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid0812.020229","article-title":"Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model","volume":"8","author":"Tesh","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2014.10.004_bib0405","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2014.10.004_bib0410","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"J Virol"},{"issue":"15\u201316","key":"10.1016\/j.vaccine.2014.10.004_bib0415","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0264-410X(98)00487-3","volume":"17","author":"Monath","year":"1999","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2014.10.004_bib0420","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology."},{"issue":"9853","key":"10.1016\/j.vaccine.2014.10.004_bib0425","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"issue":"7-8","key":"10.1016\/j.vaccine.2014.10.004_bib0430","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","article-title":"Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2014.10.004_bib0435","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2014.10.004_bib0440","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis."},{"issue":"9951","key":"10.1016\/j.vaccine.2014.10.004_bib0445","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.vaccine.2014.10.004_bib0450","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2014.07.008","article-title":"Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials","volume":"32","author":"da Costa","year":"2014","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2014.10.004_bib0455","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2014.10.004_bib0460","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2014.10.004_bib0465","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/infdis\/jiq074","article-title":"Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination","volume":"203","author":"Smith","year":"2011","journal-title":"J Infect Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14013644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14013644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T04:54:59Z","timestamp":1598417699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14013644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X14013644"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.10.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk\/benefit assessment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}